Arcellx Revenue and Competitors
Estimated Revenue & Valuation
- Arcellx's estimated annual revenue is currently $33.3M per year.
- Arcellx's estimated revenue per employee is $193,750
- Arcellx's total funding is $200M.
Employee Data
- Arcellx has 172 Employees.
- Arcellx grew their employee count by 27% last year.
Arcellx's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Head Medical Affairs | Reveal Email/Phone |
2 | VP Cell Process Science | Reveal Email/Phone |
3 | Head MSAT | Reveal Email/Phone |
4 | Head Value & Access | Reveal Email/Phone |
5 | VP, Clinical Research and Regulatory Affairs | Reveal Email/Phone |
6 | VP Quality | Reveal Email/Phone |
7 | VP, Quality | Reveal Email/Phone |
8 | Controller | Reveal Email/Phone |
9 | VP, Investor Relations | Reveal Email/Phone |
10 | Head Supply Chain | Reveal Email/Phone |
Arcellx Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.3M | 2 | -60% | N/A | N/A |
#2 | $2.9M | 38 | -31% | $17.5M | N/A |
#3 | $2.9M | 38 | -33% | $10.5M | N/A |
#4 | $19.8M | 128 | 0% | $69.4M | N/A |
#5 | $9.6M | 62 | -15% | N/A | N/A |
#6 | $1.4M | 9 | 0% | N/A | N/A |
#7 | $2.5M | 16 | 0% | N/A | N/A |
#8 | $7.4M | 48 | 0% | N/A | N/A |
#9 | $0.2M | 1 | -83% | N/A | N/A |
#10 | $1.7M | 11 | 22% | N/A | N/A |
What Is Arcellx?
Arcellx is a clinical-stage biopharmaceutical company developing novel, adaptive and controllable cell therapies for the treatment of patients with cancer and autoimmune diseases. The Company's proprietary ARC-sparX platform separates the tumor-recognition and tumor-killing functions of conventional CAR-T cell therapies: (1) sparX (soluble protein antigen-receptor X-linkers) proteins recognize and bind specific antigens on diseased cells and flag those cells for destruction; and (2) ARC-T (Antigen Receptor Complex-T) cells bind the sparX proteins and kill the flagged cells. Arcellx has developed a collection of sparX proteins that bind different cell surface antigens. Administration of alternate sparX proteins can redirect ARC-T cells to different disease antigens to potentially address relapsed and refractory disease due to tumor heterogeneity or antigen escape. Additionally, ARC-T cell activity can be curbed as needed by controlling the dose and frequency of sparX administration.
keywords:N/A
$200M
Total Funding
172
Number of Employees
$33.3M
Revenue (est)
27%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Arcellx News
According to Zacks, analysts expect that Arcellx will report full-year earnings of ($4.52) per share for the current financial year,...
Arcellx Presents Pre-Clinical Data for ACLX-002, a Novel CD123-targeted Universal CAR-T Cell Therapy for Relapsed or Refractory Acute Myeloid...
About Arcellx, Inc. Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies...
Arcellx, a Gaithersburg, Md.-based clinical-stage biopharmaceutical company advancing a pipeline of adaptive and controllable cell therapies, raised $115m in Series C financing. The round was co-led by Samsara BioCapital and CAM Capital, joined by new investors Adage, Asymmetry, CaaS Capital, C ...
Other Companies in Gaithersburg
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $28.1M | 181 | -7% | N/A |
#2 | $29M | 182 | 10% | N/A |
#3 | $15M | 191 | 9% | N/A |
#4 | $25.2M | 191 | 6% | N/A |
#5 | $62.8M | 197 | N/A | N/A |